SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-21-022925
Filing Date
2021-09-30
Accepted
2021-09-30 16:01:16
Documents
14
Period of Report
2021-09-27
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K navb20210929_8k.htm   iXBRL 8-K 28624
2 EXHIBIT 99.1 ex_287744.htm EX-99.1 12908
  Complete submission text file 0001437749-21-022925.txt   179595

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA navb-20210927.xsd EX-101.SCH 3593
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE navb-20210927_def.xml EX-101.DEF 11424
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE navb-20210927_lab.xml EX-101.LAB 15310
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE navb-20210927_pre.xml EX-101.PRE 11584
7 EXTRACTED XBRL INSTANCE DOCUMENT navb20210929_8k_htm.xml XML 2568
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35076 | Film No.: 211295081
SIC: 2835 In Vitro & In Vivo Diagnostic Substances